Investigating the steroids and long-acting β2-agonists combination: Why do we need more?

European Respiratory Journal

Volumn 23, Issue 4, 2004, Pages 501-502

  Papi, A ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; DEXAMETHASONE; DNA; FLUTICASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; LYSOPHOSPHOLIPID; PHOSPHOLIPASE A2; SALMETEROL; THROMBOCYTE ACTIVATING FACTOR;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BREATHING MUSCLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DNA BINDING; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; EDITORIAL; GENETIC TRANSCRIPTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SMOOTH MUSCLE RELAXATION;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; BRONCHODILATOR AGENTS; CELL ADHESION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 1842481382     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.04.00129104     Document Type: Editorial

References (19)

1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344: 219-224.
2. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Br Med J 2000; 320: 1368-1373.
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998; 157: S1-53.
4. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: Meta-analysis. Br Med J 2001; 323: 253-256.
5. Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999; 104: S10-S17.
6. Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002; 110: S261-268.
7. Mak JC, Hisada T, Salmon M, Barnes PJ, Chung KF. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol 2002; 135: 987-996.
8. Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360: 1293-1299.
9. 2-integrin adhesion of eosinophils by salmeterol and fluticasone. Eur Respir J 2004; 23: 511-517.
10. Myou S, Sano H, Fujimura M, et al. Blockade of eosinophil migration and airway hyperresponsiveness by cPLA2-inhibition. Nat Immunol 2001; 2: 145-149.
11. Zhu X, Munoz NM, Kim KP, Sano H, Cho W, Leff AR. Cytosolic phospholipase A2 activation is essential for beta 1 and beta 2 integrin-dependent adhesion of human eosinophils. J Immunol 1999; 163: 3423-3429.
12. Sano A, Munoz NM, Sano H, et al. Inhibition of cPLA2 translocation and leukotriene C4 secretion by fluticasone propionate in exogenously activated human eosinophils. Am J Respir Crit Care Med 1999; 159: 1903-1909.
13. Dennis EA. Phospholipases. In: P. Boyer, ed. The Enzyme. New York, Academic Press, 1983; pp. 307-353.
14. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model. J Exp Med 1996; 183: 195-201.
15. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144-2148,
16. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003; 167: 199-204.
17. Wedi B, Wieczorek D, Stunkel T, Breuer K, Kapp A. Staphylococcal exotoxins exert proinflammatory effects through inhibition of eosinophil apoptosis, increased surface antigen expression (CD11b, CD45, CD54, and CD69), and enhanced cytokine-activated oxidative burst, thereby triggering allergic inflammatory reactions. J Allergy Clin Immunol 2002; 109: 477-484.
18. Spoelstra FM, Kauffman HF, Hovenga H, Noordhoek JA, de Monchy JG, Postma DS. Effects of budesonide and formoterol on eosinophil activation induced by human lung fibroblasts. Am J Respir Crit Care Med 2000; 162: 1229-1234.
19. Gonzalez Rodriguez R, Silvestri M, Cordone A, Salami A, Rossi GA. Inhibition of eosinophil transepithelial migration and downregulation of adhesion molecule expression on eosinophils and airway epithelial cells induced by budesonide. Pulm Pharmacol Ther 2000; 13: 31-38.